Brief: Sichuan Kelun-Biotech Biopharma Says Primary Endpoint Met For Phase 3 Study Of Lung Cancer Treatment
15/07/2026 02:20
BRIEF-Sichuan Kelun-Biotech Biopharma Says Primary Endpoint Met For Phase 3 Study Of Lung Cancer Treatment July 15 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:
PRIMARY ENDPOINT MET FOR PHASE 3 STUDY OF TROP2 ADC SACITUZUMAB TIRUMOTECAN WITH PEMBROLIZUMAB
Further company coverage: 6990.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sichuan Kelun-Biotech Biopharmaceutical
See all newsBrief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes To CZB Structured Deposit VI For RMB500 Mln
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Accepts New Indication Application For SAC-TMT
Brief: Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study
China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts HY Net Income Attributable Of RMB 388 MLN